Pharmadrug Inc (PHRX.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 317 | 322 | 321 | 323 | 330 |
| Income taxes - deferred | -560 | -92 | -94 | -87 | N/A |
| Accounts receivable | 0 | 22 | 136 | -50 | 11 |
| Accounts payable and accrued liabilities | 69 | -42 | -164 | 14 | -696 |
| Other Working Capital | 54 | -43 | -38 | -105 | -595 |
| Other Operating Activity | -1,009 | -1,022 | -882 | -1,515 | 608 |
| Operating Cash Flow | $-1,130 | $-855 | $-720 | $-1,420 | $-342 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 1 | -1 | N/A | N/A | -18 |
| Net Acquisitions | 0 | -53 | N/A | 362 | -16 |
| Sale Of Investment | 0 | N/A | N/A | 1,214 | N/A |
| Purchase Sale Intangibles | -5 | -33 | -4 | N/A | 0 |
| Other Investing Activity | 0 | 0 | 0 | 0 | 1,623 |
| Investing Cash Flow | $-5 | $-87 | $-4 | $1,576 | $1,589 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 0 | 250 |
| Debt Repayment | -14 | -17 | -17 | -17 | -680 |
| Other Financing Activity | 0 | -111 | 90 | 862 | 1,403 |
| Financing Cash Flow | $-14 | $-128 | $73 | $845 | $974 |
| Exchange Rate Effect | 359 | -83 | 18 | 396 | -356 |
| Beginning Cash Position | 1,747 | 2,900 | 3,533 | 2,135 | 269 |
| End Cash Position | 958 | 1,747 | 2,900 | 3,533 | 2,135 |
| Net Cash Flow | $-1,148 | $-1,070 | $-651 | $1,002 | $2,222 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,130 | -855 | -720 | -1,420 | -342 |
| Capital Expenditure | -5 | -34 | -4 | N/A | -17 |
| Free Cash Flow | -1,134 | -889 | -725 | -1,420 | -359 |